Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy [Seeking Alpha]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Seeking Alpha
Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candidates in their pipeline. Thus, Elevidys's monopoly could be under a threat. Based on my technology assessment, only two product candidates have the potential to disrupt Elevidys monopoly in the next two to three years. Thus, I consider that CTLT's and SRPT's revenue driven by Elevidys is not only safe, but poised to grow given the label expansion in the U.S. Thesis Catalent ( NYSE: CTLT ), who is partially responsible for manufacturing Elevidys on behalf of Sarepta, observed its shares gaining approximately 3% last Friday given the recent FDA approval of Elevidys label expansion. In a recent article , I discussed the Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Catalent, Inc. (NYSE: CTLT) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.MarketBeat
- Catalent cut to neutral at Baird as analyst unable to find valuation in a deal break [Seeking Alpha]Seeking Alpha
- Catalent, Inc. (NYSE: CTLT) had its "neutral" rating re-affirmed by analysts at Robert W. Baird. They now have a $63.50 price target on the stock.MarketBeat
- Asia-Pacific CDMO Market Share Analysis, Industry Trends & Growth Forecasts 2024-2029: Demand For Injectable Dose Formulation is Rising in the Market [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 8/29/24 - Miss
CTLT
Sec Filings
- 9/27/24 - Form 4
- 9/26/24 - Form 144
- 9/6/24 - Form 10-K
- CTLT's page on the SEC website